RNA Formulation Articles

1. Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery 9/9/2026

   We discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.

2. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

3. Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics 8/19/2026

   Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

4. Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics 8/11/2026

   RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.

5. A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products 8/10/2026

   NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

6. The Second Holy Grail Of Gene Editing: Large Knock-Ins 8/10/2026

   Exploring the race to achieve large gene knock-ins, emerging editing platforms, and how overcoming this challenge could unlock therapies for many inherited diseases.

7. From Baby KJ To Global Access: The 3 Pillars Of Next-Gen mRNA Expansion 8/8/2026

   Obviously, the transition from RNA vaccines to therapeutics is an “expansion” all on its own; but to do this successfully, we need to expand our science, our products’ deliverability, and our patient access. In the following article, I highlight a few of the best practices and/or innovations that came up in conversation during this event that will play a significant role in helping us expand mRNA’s reach, both scientifically and therapeutically.

8. The Preclinical Gauntlet: Securing Capital And Designing Regulatory Pathways For Ultra-Rare ASO Drugs (Pt. 2) 8/7/2026

   SynaptixBio CEO Dan Williams explains why funding, regulatory strategy, toxicology, and disciplined execution — not just science — determine success in advancing ultra-rare ASO therapies.

9. Reprogramming The Tumor Microenvironment: Why RNA Immunotherapy Is Targeting Liver Metastases (Pt. 1) 8/5/2026

   RNA/DNA immunotherapy may overcome liver metastases by reprogramming innate immunity, restoring interferon signaling, and improving responses to checkpoint inhibitors.

10. Beyond Protein Targets: Why The Regulatory Genome Could Redefine RNA Medicine (Pt. 1) 8/4/2026

    Explore how the regulatory genome and lncRNAs are shifting RNA medicine beyond protein targets, enabling cell-state reprogramming to treat disease at its source.